Total trials
69
Active
8
Phase 3
8
Total enrollment
33,668
Pipeline matrix
Showing 12 of 12 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Fang Le Shu | — | — | — | — | — | 1 | |
| Guo Na Fen | — | — | — | — | — | 1 | |
| Leuprorelin | — | — | — | — | — | 1 | |
| LBVD | — | — | — | — | — | 2 | |
| Pentavalent vaccine and Inactivated Polio vaccine | — | — | — | — | — | 2 | |
| DTaP-HepB-IPV-Hib vaccine | — | — | — | — | 2 | ||
| LR20062 | — | — | — | — | — | 1 | |
| Test drug: Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg | — | — | — | — | — | 1 | |
| Reference drug: Gemigliptin (Zemiglo) 50mg, Dapagliflozin/metformin (Xigduo XR) 10/1000 mg | — | — | — | — | — | 1 | |
| Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg | — | — | — | — | — | 1 | |
| Phase 1a: LB-LR1109 | — | — | — | — | — | 1 | |
| Phase 1b: LB-LR1109 and Atezolizumab | — | — | — | — | — | 1 |
Next readouts
- 2025-06-30
- 2025-09-30
- 2026-02-28
- 2026-07-31
- 2026-11
- 2027-11
- 2029-08-30
Top conditions
- Gout10
- Hyperuricemia10
- Poliomyelitis8
- Diphtheria7
- Tetanus7
- Pertussis7
- Hepatitis B7
- Healthy6
Frequently asked questions about LG Chem
- How many clinical trials does LG Chem have on ClinicalTrials.gov?
- LG Chem is listed as the lead sponsor on 69 clinical trials in ClinicalTrials.gov, 8 of which are currently active (recruiting, enrolling, or ongoing).
- How many of LG Chem's trials are in Phase 3?
- 8 of LG Chem's trials are in Phase 3, spread across 12 active drug programs.
- What therapeutic areas does LG Chem focus on?
- LG Chem's most-studied conditions on ClinicalTrials.gov are Gout, Hyperuricemia, Poliomyelitis, Diphtheria, Tetanus.
- When are LG Chem's next clinical trial readouts?
- LG Chem has 7 upcoming primary-completion readouts tracked here; the soonest is “Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age”, expected around 2025-06-30.